A Phase II, Randomized, open-label study to evaluate low-dose Pembrolizumab plus Chemotherapy vs Chemotherapy as Neoadjuvant Therapy for localized Triple Negative Breast Cancer (TNBC). [PLANeT Trial - Pembrolizumab Low Dose in Addition to NACT in TNBC].
Arora A, Bhaskarane H, Tansir G, Bakhshi S, Gogia A, Kumar A, Jain R, Kalra K, Vishvam D, Mathur S, Rathore R, Shamim SA, Dhamija E, Rangarajan K, Tanwar P, Prasad CP, Kumar S, Gupta I, Mani K, Upadhyay AD, Diwakar MK, Vasudeva P, Verma N, Agstam S, Seenu V, Prashad R, Bansal VK, Dhar A, Krishna A, Ranjan P, Suhani S, Prakash O, Kataria K, Kumar B, Mishra A, Sharma J, Bansal B, Saikia J, Bhasker S, Haresh KP, Gupta S, Saini SK, Mallick S, Batra A.
Arora A, et al. Among authors: mathur s.
Ann Oncol. 2025 Dec 22:S0923-7534(25)06335-5. doi: 10.1016/j.annonc.2025.12.015. Online ahead of print.
Ann Oncol. 2025.
PMID: 41443410